If you are wondering what the best stock to pick up at the moment, we suggest you read this list
?3 stocks up 195% to 467%, according to Wall Street!
Plug power #plug estimated growth potential of 195%
Analyst Amit Dayal of HC Wainwright has assigned a target price of $78.
The company is in the hydrogen fuel cell business. Alternative energy sources, including hydrogen fuel cells, are becoming increasingly popular in efforts to fight climate change.
Plug Power entered into two important partnerships in January. SK Group bought a 10% stake in Plug and plans to work with the company to build fuel cell vehicles and hydrogen refueling stations throughout South Korea. And also with French automaker Renault will focus on the European light commercial vehicle market.
Zogenix #zgnx estimated growth potential of 319%
The most optimistic target price from Wall Street is $62.
The optimism around the company stems from FDA approval of Fintepla, a drug designed to treat a variety of seizure-related conditions. Zogenix plans to file a supplemental new drug application (sNDA) in the third quarter. If the drug is approved, commercial sales will begin as early as the first half of 2022. Fintepla’s rapid growth should make Zogenix one of the fastest growing stocks for at least the next three years.
Intercept Pharmaceuticals #icpt estimated growth potential of 467%
Yasmin Rahimi of Piper Sandler gives a target price of $82.
A small-cap biotech company specializing in liver disease.
Obeticholic Acid (OCA) as a treatment for nonalcoholic steatohepatitis (NASH) could help Intercept. NASH affects 2% to 5% of the U.S. adult population, is valued at $35 billion, and there are currently no FDA-approved drugs on the market.
In addition, OCA is FDA-approved for the treatment of predominantly biliary cholangitis (PBC). This could generate more than $350 million in annual revenue for Intercept.